Relmada Therapeutics Inc
NASDAQ:RLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.4), the stock would be worth $1.62 (78% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.1 | $7.25 |
0%
|
| 3-Year Average | 1.4 | $1.62 |
-78%
|
| 5-Year Average | 2 | $2.41 |
-67%
|
| Industry Average | 3.8 | $4.45 |
-39%
|
| Country Average | 2.5 | $2.97 |
-59%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
760.5m USD | 6.1 | -9.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 32.7 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 6.8 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.4 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 6.1 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 6.1 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 5.4 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 5.6 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 1.8 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 6.4 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Relmada Therapeutics Inc
Glance View
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Coral Gables, Florida and currently employs 10 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).
